Zokinvy Capsule
NDC 42358-450
Product Information
Zokinvy (lonafarnib) is a NDA-approved product labeled by Sentynl Therapeutics, Inc.. This medication is typically used as a breast cancer resistance protein inhibitors [moa]. It is supplied as a yellow capsule for oral administration. This product entry covers the primary NDC 42358-450 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
LNF;50
Code Structure Chart
Product Details
What is NDC 42358-450?
What are the uses of this product?
What are Active Ingredients of this product?
- LONAFARNIB 50 mg/1 - inhibitor of farnesyl protein transferase
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- LONAFARNIB (UNII: IOW153004F)
- LONAFARNIB (UNII: IOW153004F) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- POVIDONE (UNII: FZ989GH94E)
- POLOXAMER 188 (UNII: LQA7B6G8JG)
- CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2467582 - lonafarnib 50 MG Oral Capsule
- RxCUI: 2467588 - Zokinvy 50 MG Oral Capsule
- RxCUI: 2467588 - lonafarnib 50 MG Oral Capsule [Zokinvy]
- RxCUI: 2467590 - lonafarnib 75 MG Oral Capsule
- RxCUI: 2467592 - Zokinvy 75 MG Oral Capsule
Which are the Pharmacologic Classes of this product?
- Breast Cancer Resistance Protein Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 2C19 Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 2C8 Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 3A Inhibitors - [MoA] (Mechanism of Action)
- Farnesyltransferase Inhibitor - [EPC] (Established Pharmacologic Class)
- Farnesyltransferase Inhibitors - [MoA] (Mechanism of Action)
- Organic Anion Transporting Polypeptide 1B1 Inhibitors - [MoA] (Mechanism of Action)
- Organic Anion Transporting Polypeptide 1B3 Inhibitors - [MoA] (Mechanism of Action)
- P-Glycoprotein Inhibitors - [MoA] (Mechanism of Action)
* Please review the full disclaimer at the bottom of this page.